YundingXinyao (01952.HK): Nafucon has been granted full approval by the China National Medical Products Administration for the treatment of adult patients with primary IgA nephropathy at risk of disease progression.

The Zhixin Finance APP reported that Yun Dingxin Yao (01952.HK) issued an announcement that NEFECON has been fully approved by the China National Medical Products Administration, lifting the restrictions on proteinuria levels, for the treatment of primary IgA nephropathy in adults with a risk of disease progression. This full approval means that NEFECON has become the first and only IgA nephropathy treatment drug in China to receive complete approval from the Chinese drug regulatory authority.